2026-10-08
Ribobio Submits Phase I Clinical Trial Application for siRNA Drug RBD3133 Targeting INHBE to EU
Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for...